Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production

Journal of Autoimmunity

Volumn 16, Issue 1, 2001, Pages 47-58

  Stošić Grujičić, Stanislava ^a   Maksimović, Danijela ^a   Badovinac, Vladimir ^a   Samardžić, Tatjana ^a   Trajković, Vladimir ^b   Lukić, Miodrag ^b,c   Stojković, Marija Mostarica ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cytokines; Dark Agouti rats; IDDM; Nitric oxide; Pentoxifylline

Indexed keywords

NITRIC OXIDE; PENTOXIFYLLINE; XANTHINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; DRUG EFFECT; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; RAT;

EID: 0035110543     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0456     Document Type: Conference Paper

References (70)

1. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy
2. Effect of methylxantine derivatives on T cell activation
3. Pentoxitylline inhibits adhesion and activation of human T lymphocytes
4. Methylxanthine-induced inhibition of the antigen- and superantigen-specific activation of T and B lymphocytes
5. Effect of pentoxifylline on phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells
6. Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression
7. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor
8. Suppressive effects of pentoxifylline on natural killer cell activity
9. Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis
10. Pentoxifylline in the treatment of experimental peritonitis in rats
11. Group B streptococcus induces tumor necrosis factor in neonatal piglets. Effect of the tumor necrosis factor inhibitor pentoxifylline on hemodynamics and gas exchange
12. Role of activated macrophages in augmentation of endotoxin hepatotoxicity
13. Pentoxifylline suppresses irritant and contact hypersensitivity reactions
14. Hypothesis: Is there a place for pentoxifylline in the treatment of rheumatoid arthritis?
15. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats
16. Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline
17. The phosphodiesterase inhibitors Pentoxifylline and Rolipram prevent diabetes in NOD mice
18. Streptozotocin-induced pancreatic insulitis: A new model of diabetes mellitus
19. Streptozotocin-induced diabetes in mice lacking αβ T cells
20. Effector mechanisms in low dose streptozotocin induced diabetes
21. Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus
22. + T cells in the pathogenesis of organ-specific autoimmune diseases
23. Inhibition of nitric oxide generation affects the induction of diabetes by streptozotocin in mice
24. w-nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E rats
25. G-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat
26. Experimental allergic uveitis in the rat: Cellular characteristics and strain differences in susceptibility to the induction
27. Homologous type II collagen-induced arthritis in rats. Characterisation of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation
28. Analysis of T cell subsets after induction of experimental autoimmune encephalomyelitis in susceptible and resistant strains of rats
29. Strain variation in autoimmtmitv: Attempted tolerization of DA rats results in the induction of experimental autoimmune encephalomyelitis
30. Immunological basis of the strain differences in susceptibility to low-dose streptozotocin-induced diabetes in rats
31. Rapid isolation of pancreatic islets from collagenase digested pancreas by sedimentation through Percoll at unit gravity
32. Low-dose streptozotocin-induced diabetes in mice
33. Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-γ. Increased TNF-α but not IL-1 activity
34. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages
35. Pentoxifylline prevents autoimmune mediated inflammation in low dose streptozotocin induced diabetes
36. Multiple low dose streptozotocin induced systemic MHC expression in mice by triggering T cells to release IFN-γ
37. Cellular immune response to diverse islet cell antigens in IDDM
38. Paradoxical antidiabetogenic effect of γ-interferon in DP-BB rats
39. Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline
40. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases
41. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation
42. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis
43. Susceptibility to experimental T-cell-dependent autoimmunity and reactivity to self-major histocompatibility complex antigens
44. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: Role of cAMP in T cell proliferation
45. Structure and function of adhesion receptors in leukocyte trafficking
46. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation?
47. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin
48. Oral insulin treatment suppresses diabetes in transgenic mice
49. Pentoxifylline decreases in vivo and in vitro tumor necrosis factor-alpha (TNF-α) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL)
50. Pentoxifylline in vivo downregulates the release of IL-1β,IL-6, IL-8 and tumor necrosis factor-α by human peripheral blood mononuclear cells
51. Inhibition of human interleukin-12 production by pentoxifylline
52. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus
53. Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ
54. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor α
55. Inhibition of type 1 diabetes in BB rats with recombinant human tumor necrosis factor-α
56. Nitric oxide: A pathogenic factor in autoimmunity
57. Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: Identification of iNOS expressing cells and relationships to cytokines expressed in the islets
58. Evidence that β-cell death in the nonobese diabetic mouse is Fas independent
59. Nitric oxide in autoimmune disease: Cytotoxic or regulatory mediator?
60. Nephroprotective mechanism(s) of pentoxifylline-reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release
61. Pentoxifylline potentiates nitric oxide production and growth suppression in IFN-γ-treated L929 fibroblasts
62. Inhibition of macrophage Ia expression by nitric oxide
63. Molecular basis of 'suppressor' macrophages. Arginine metabolism via the nitric oxide synthetase pathway
64. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells
65. Inhibition of IL-2 production by nitric oxide: A novel self-regulatory mechanism for Th1 cell proliferation
66. IFN-γ is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: A possible role for nitric oxide
67. Nitric oxide via an inducible isoform of nitric oxide synthase is a possible factor to eliminate cells from the central nervous system of mice with experimental allergic encephalomyelitis
68. Nitric oxide suppresses human T lymphocyte proliferation through IFN-γ-dependent and IFN-γ-independent induction of apoptosis
69. Cytolitic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
70. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus